<p>Bicalutamide is a non-steroidal androgen receptor&nbsp;inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic&nbsp;carcinoma&nbsp;is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.<br />
<br />
When Bicalutamide is combined with luteinizing hormone releasing hormone (LHRH) analog&nbsp;therapy, the suppression of&nbsp;serum&nbsp;testosterone&nbsp;induced by the LHRH analog is not affected. However, in&nbsp;clinical trials&nbsp;with Bicalutamide as a single agent for&nbsp;prostate cancer, rises in serum testosterone and estradiol have been noted.<br />
<br />
In a subset of patients who have been treated with Bicalutamide and an&nbsp;LHRH agonist, and who discontinue Bicalutamide therapy due to progressive advanced prostate&nbsp;cancer, a reduction in&nbsp;Prostate Specific Antigen&nbsp;(PSA) and/or clinical improvement (antiandrogen&nbsp;withdrawal phenomenon) may be observed.</p>